Lipoprotein(a), apolipoprotein(a) polymorphism, and insulin treatment in type II diabetic patients.
Buscaglia
P
P
Gazzaruso
C
C
Garzaniti
A
A
Bonetti
G
G
Fratino
P
P
Geroldi
D
D
D000284:Administration, Oral; D001053:Apolipoproteins / Q000097:blood* / Q000235:genetics; D053241:Apoprotein(a); D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics; D003925:Diabetic Angiopathies / Q000097:blood; D005260:Female; D019270:Fructosamine; D006442:Glycated Hemoglobin / Q000032:analysis; D006595:Hexosamines / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000097:blood; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use*; D017270:Lipoprotein(a) / Q000097:blood* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D011110:Polymorphism, Genetic; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D053241:Apoprotein(a); D001786:Blood Glucose; D002784:Cholesterol; D019270:Fructosamine; D006442:Glycated Hemoglobin; D006595:Hexosamines; D007004:Hypoglycemic Agents; D007328:Insulin; D017270:Lipoprotein(a); D014280:Triglycerides